13F-HR filed by Artia Global Partners LP
Artia Global Partners LP filed this 13F-HR for the quarter ended 2023-09-30, filed 2023-11-14, with 27 holding rows worth $240,556,497.
- Accession
- 0001937964-23-000006
- Filer
- CIK 1937964
- Filed
- 2023-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2023
A holdings report, 27 entries on the cover page, a total value of $240,556,497 stated on the cover page (in dollars after the unit check, H1), rows summing to $240,556,497 with VALUE read as dollars as filed, 13F file number 028-23071. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| NOVO-NORDISK A S ADR | 670100205 | ADR | 681,812 | $62,003,983 | dollars as filed | |
| Merck & Co.,Inc. | 58933Y105 | COM | 329,200 | $33,891,140 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 49,238 | $24,206,878 | dollars as filed | |
| Eli Lilly and Company | 532457108 | COM | 26,193 | $14,069,046 | dollars as filed | |
| AbbVie,Inc. | 00287Y109 | COM | 90,821 | $13,537,778 | dollars as filed | |
| ASTRAZENECA PLC SPONSORED ADR | 046353108 | ADR | 190,752 | $12,917,725 | dollars as filed | |
| SEAGEN INC | 81181C104 | COM | 51,175 | $10,856,776 | dollars as filed | |
| ROIVANT SCIENCES LTD | G76279101 | SHS | 914,023 | $10,675,789 | dollars as filed | |
| 89BIO INC | 282559103 | COM | 465,465 | $7,186,780 | dollars as filed | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 78,465 | $6,942,583 | dollars as filed | |
| SAREPTA THERAPEUTICS INC | 803607100 | COM | 57,162 | $6,929,178 | dollars as filed | |
| Vertex Pharmaceuticals Incorporated | 92532F100 | COM | 18,314 | $6,368,510 | dollars as filed | |
| AXSOME THERAPEUTICS INC. COM | 05464T104 | Stock | 87,848 | $6,139,697 | dollars as filed | |
| NEUROCRINE BIOSCIENCES INC | 64125C109 | COM | 45,000 | $5,062,500 | dollars as filed | |
| VIKING THERAPEUTICS INC | 92686J106 | COM | 383,580 | $4,246,231 | dollars as filed | |
| ALNYLAM PHARMACEUTICALS INC COM | 02043Q107 | Stock | 15,971 | $2,828,464 | dollars as filed | |
| INTRA-CELLULAR THERAPIES INC | 46116X101 | COMMON STOCK | 41,600 | $2,166,944 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 38,555 | $1,965,534 | dollars as filed | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 112,340 | $1,873,831 | dollars as filed | |
| PLIANT THERAPEUTICS INC | 729139105 | COM | 100,000 | $1,734,000 | dollars as filed | |
| CHARLES RIV LABS INTL INC | 159864107 | COM | 6,905 | $1,353,242 | dollars as filed | |
| Thermo Fisher Scientific Inc. | 883556102 | COM | 2,109 | $1,067,513 | dollars as filed | |
| WATERS CORP COM | 941848103 | Stock | 2,845 | $780,127 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 45,253 | $623,134 | dollars as filed | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 41,261 | $615,202 | dollars as filed | |
| BIOMEA FUSION INC | 09077A106 | CMN | 25,452 | $350,220 | dollars as filed | |
| GRITSTONE BIO INC | 39868T105 | COM | 95,170 | $163,692 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001937964-23-000006 | this filing | 2023-11-14 | acceptance time not in the bulk data set |